EntryPoint Capital’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$371K Buy
+1,716
New +$328K 0.09% 452
2025
Q4
Sell
-3,319
Closed -$465K 670
2025
Q3
$465K Buy
3,319
+258
+8% +$34.9K 0.18% 194
2025
Q2
$384K Sell
3,061
-118
-4% -$14.7K 0.19% 182
2025
Q1
$435K Buy
3,179
+1,540
+94% +$220K 0.2% 154
2024
Q4
$251K Buy
1,639
+55
+3% +$9.28K 0.11% 478
2024
Q3
$307K Buy
+1,584
New +$331K 0.17% 239
2024
Q2
Sell
-167
Closed -$36K 1424
2024
Q1
$36K Buy
+167
New +$39.1K 0.03% 899

Other funds holding BIIB

EntryPoint Capital's BIIB Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Biogen (BIIB) in Q2 2026: 1,716 shares worth $371K. The stake represents 0.09% of the portfolio and ranks #452 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in BIIB as recently as Q3 2025.

EntryPoint Capital first reported a position in BIIB in Q1 2024 and has held it in 7 quarters since. The position peaked at $465K in Q3 2025. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • EntryPoint Capital held 1,716 shares of Biogen worth $371K as of Q2 2026.
  • Biogen was a new EntryPoint Capital position in Q2 2026.
  • Biogen made up 0.09% of EntryPoint Capital's portfolio in Q2 2026, its #452 holding.
  • EntryPoint Capital first reported a position in Biogen in Q1 2024 and has held it in 7 quarters since.
  • EntryPoint Capital's Biogen position peaked at $465K in Q3 2025.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.